

Factsheet

Investment Company with Variable Capital (SICAV) according to Luxembourg Laws – UCITS

Marketing communication / Financial promotion - For retail/non-qualified investors: CH, GB and professional investors: AT, DE, ES, LU

Investment focus

Bellevue Healthcare Trust intends to invest in a concentrated portfolio of listed or quoted equities in the global healthcare industry. The investable universe for the fund is the global healthcare industry including companies within industries such as pharmaceuticals, biotechnology, medical devices and equipment, healthcare insurers and facility operators, information technology (where the product or service supports, supplies or services the delivery of healthcare), drug retail, consumer healthcare and distribution. There are no restrictions on the constituents of the funds portfolio by index benchmark, geography, market capitalisation or healthcare industry sub-sector. Bellevue Healthcare Trust will not seek to replicate the benchmark index in constructing its portfolio. The fund takes ESG factors into consideration while implementing the aforementioned investment objectives.


Fund facts

Share price	117.20
Net Asset Value (NAV)	123.54
Market capitalisation	GBP 139.58 mn
Investment manager	Bellevue Asset Management (UK) Ltd.
Administrator	NSM Funds (UK) Limited
Launch date	01.12.2016
Fiscal year end	Nov 30
Benchmark (BM)	MSCI World Healthcare NR
ISIN code	GB00BZCNLL95
Bloomberg	BBH LN Equity
Number of ordinary shares	119,098,416
Management fee (p.a.)	0.95%
Performance fee (p.a.)	none
Min. investment	n.a.
Legal entity	UK Investment Trust (plc)
EU SFDR 2019/2088	Article 8

Key figures

Beta	1.13
Correlation	0.63
Volatility	22.4%
Tracking Error	17.57
Active Share	73.43
Sharpe Ratio	-0.41
Information Ratio	-0.37
Jensen's Alpha	-6.30

Indexed performance since launch



Cumulative & annualised performance

Cumulative

	1M	YTD	1Y	3Y	5Y	10Y	ITD
Share	0.2%	-13.6%	-16.1%	-21.6%	-14.8%	n.a.	57.8%
NAV	1.9%	-13.5%	-20.0%	-20.3%	-10.6%	n.a.	65.7%
BM	1.3%	-3.4%	-8.4%	1.9%	26.5%	n.a.	103.3%


Annualised

	1Y	3Y	5Y	10Y	ITD
Share	-16.1%	-7.8%	-3.2%	n.a.	5.3%
NAV	-20.0%	-7.3%	-2.2%	n.a.	5.9%
BM	-8.4%	0.6%	4.8%	n.a.	8.4%

Annual performance

	2020	2021	2022	2023	2024	YTD
Share	29.1%	16.6%	-21.0%	7.0%	-6.5%	-13.6%
NAV	25.7%	15.2%	-11.1%	2.4%	-6.7%	-13.5%
BM	10.3%	20.8%	5.8%	-1.6%	3.1%	-3.4%

Rolling 12-month-performance



Source: Bellevue Asset Management, 30.09.2025; all figures in GBP %, total return / BVI-methodology

Past performance is not a reliable indicator of future results and can be misleading. Changes in the rate of exchange may have an adverse effect on prices and incomes. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. The reference benchmark is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to the fund, thus the performance of a benchmark is not a reliable indicator of future performance of the Bellevue Healthcare Trust to which it is compared. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred.

Welcome to our September update. While the summer sunshine is fading away, the light shines brightly on the healthcare sector, as a confluence of factors begin to re-energize investor returns in certain areas as fundamentals improve.

Further positive-sounding progress has been made on US drug pricing and pharma tariffs. While one cannot describe two vague agreements as definitive, the base case for now is a much better one than anyone imagined a few months ago, and the Administration's openness to horse trading for quick results augurs well for a soft landing.


The healthcare sector has felt unloved and ignored for most of the year. Recent agreements with selected pharma companies on pricing and tariff matters argue strongly for a reconsideration, as does the current over-concentration of investor weightings toward technology, and the relative valuation opportunity in our sector remains compelling, as the trust's net asset value (NAV) performance in the first half of October attests.

Monthly review

The Trust

During September, the trust's NAV total return was +1.6% in USD terms (+1.9% in GBP), with the NAV rising to 123.5 bps. This represented a total return outperformance of the MSCI World Health Care Index of 59 bps.

The evolution of the NAV throughout the month is illustrated in Figure 1 below, which again shows a more positive size factor effect from SMID-cap healthcare, for the fifth consecutive month, driven mostly by biotechnology shares (the USD total return of the NASDAQ Biotechnology Index over the month was +4.4%).



Source: Bellevue Asset Management, 30.09.2025

The evolution of the subsector weightings is summarized in Figure 2 opposite. The portfolio grew from 43 to 45 positions, with additions in focused therapeutics and diagnostics. The leverage ratio increased from -3.3% of gross assets (i.e. a small net cash position) to a modest level of gearing at +0.7%, and there was a rebalancing of the portfolio away from medtech, dental, and diagnostics to facilitate increased exposure to managed care and services.


	Subsectors end Aug 25	Subsectors end Sept 25	Change
Dental	1.5%	0.1%	Decreased
Diagnostics	19.3%	14.9%	Decreased
Distributors	4.4%	4.8%	Increased
Diversified Therapeutics	12.9%	12.9%	Unchanged
Facilities	0.2%	0.4%	Increased
Focused Therapeutics	19.5%	21.1%	Increased
Healthcare Technology	4.7%	4.8%	Increased
Managed Care	5.6%	10.0%	Increased
Med-Tech	16.4%	11.7%	Decreased
Services	6.6%	10.1%	Increased
Tools	8.9%	9.0%	Increased
	100.0%	100.0%	

Source: Bellevue Asset Management, 30.09.2025

The focused therapeutics, diversified therapeutics, and diagnostics subsectors were the largest positive contributors during the month, and medtech, healthcare technology, and tools were all net detractors from the overall performance.



The Healthcare Sector

During September, the USD total return of the MSCI World Health Care Index underperformed that of its parent MSCI World Index by 225 bps as technology-related megacaps again led the way. The evolution of healthcare sector total return versus the wider market is illustrated in Figure 3 below:



Source: Bellevue Asset Management, 30.09.2025

As noted previously, there was again a strong size bias to the performance in healthcare, with SMID caps outperforming megacaps. Interestingly, this was not really apparent in the wider market, as Chart 3 illustrates, comparing returns for the megacap Russell 1000 Index and SMID-cap Russell 2000 Index across the broad market and then healthcare specifically:



Source: Bellevue Asset Management, 30.09.2025

Several factors seem to be driving this, especially for biotechnology and specialty pharma: multiple positive clinical and regulatory outcomes, an improving financing environment, growing confidence in further cuts to US interest rates, and signs of increasing M&A activity. These sorts of trends tend to be self-reinforcing for the sector and, given the low base from where we are starting, could set up a material rally into the back end of the year.

Will larger-cap healthcare also perform? This has been a source of funds for tech investments during the year so in part investor confidence in the AI megatheme will feed into this. The other key aspect is the removal of the twin overhangs relating to uncertainty over US Government action on drug pricing and tariffs. As we noted last month, there seemed to be positive signs that we would get clarity imminently, and that has proven to be the case. We summarize what we know so far in the following section.

"TrumpRx" – what we know and what we don't know (so far)

Overview

Pharmaceutical and biotechnology stocks – together representing about 55% of the MSCI World Health Care Index – have struggled under the twin clouds of US drug-pricing reform and sector-specific Section 232 tariffs. This has fueled year-long generalist investor apathy toward healthcare broadly and these two subsectors in particular.

The market's focus has remained on AI-driven megacap technology stocks. Notably, NVIDIA's market value now exceeds that of all pharma and biotech constituents in the MSCI World Health Care Index combined. Record-high P/E ratios for tech and increasingly attractive relative valuations for healthcare have not been enough to tempt investors off the sidelines pending clarity on these policy threats.

After months of "imminent" hints, the White House forced the issue in early August by setting a September 29 deadline for major drug companies to outline plans for lowering US prices in line with President Trump's most-favored-nation (MFN) principle. The Administration also began tying these proposals to tariff relief, implying that tariffs could be deferred or avoided through MFN compliance and domestic manufacturing commitments (reshoring).

The merging of these once-distinct policy aims to deliver a political "win" had the air of a courtroom plea deal – Trump, as always, at the center. Many hoped that as long as the optics looked favorable, the substance would remain immaterial. This could only become clear once the MFN deadline passed and the market could see either what these industry proposals were or, alternatively, what Trump truly meant in terms of sanctions.

The art of the deal

Rumors initially pointed to an industry-wide compact negotiated by PhRMA, but in the end, the White House secured a single-company deal with Pfizer on September 30, followed by a second with AstraZeneca on October 10. More are expected to follow.

The agreement between the White House and Pfizer surprised the market, not because of its breadth, but due to its limited scope:

- Pfizer committed to MFN pricing for Medicaid, giving state programs access to the lowest comparable global price. Pfizer declined to specify how the MFN formula will be calculated, only noting that it "accounts for outliers" (very low-price countries). With Medicaid representing less than 5% of Pfizer's sales – and typically 10% or less for most major pharma and biotech companies (except Gilead, at ~25%) – the financial impact appears minimal, likely a low-single-digit percentage of gross profit.
- Beginning in early 2026, Pfizer will list most of its primary-care portfolio (~50% of US sales) and selected specialty brands at "discounted" prices on a new government-run TrumpRx web portal. These discounts will differ from Medicaid MFN prices, and their magnitude remains unclear.
- Pfizer also agreed to launch new US drugs at MFN-aligned prices, matching those of the MFN basket countries.
- Pfizer pledged USD 70 bn in US R&D and manufacturing investment in exchange for a three-year reprieve from Section 232 pharma tariffs. Compliance with this reshoring commitment could also qualify the company for an FDA national priority review voucher (NPRV) – a yet-to-be-formalized incentive whose terms and market value remain undefined.

The agreement leaves several key issues unresolved: the composition of the MFN country basket, the formula's precise mechanics, and how the TrumpRx portal will handle eligibility and reimbursement for insured patients. There was also no mention of extending MFN pricing beyond Medicaid to Medicare or commercial markets, nor was there any update on the proposed GLOBE and GUARD pilots at CMS/CMMI, which were expected to test such expansion.

What does seem clear is that the Administration is using tariff relief as leverage to draw drugmakers into a program with strong public optics. Trump can claim a win on drug pricing – his name emblazoned (in gold) across the TrumpRx portal – while Pfizer gains tariff relief and political goodwill for very limited financial downside.

Is this a template?

Eli Lilly was widely rumored to be the next company to announce a deal with the Administration, and there was further surprise when that mantle went to AstraZeneca. Its agreement has the same four key facets as Pfizer's: a commitment to sell drugs to Medicaid at MFN prices, direct

purchases at a “lower” price through TrumpRx, commitments to additional CapEx into the US, and parity pricing on newly launched medicines versus MFN “peer” countries. Notably, there was again no mention of Medicare or commercial channels.

Was anything notably different? Pfizer seemed to emphasize the range of medicines that will be available on TrumpRx but not focus on price levels, whereas AstraZeneca emphasized “steep” discounts on “select” medicines. Unknowns aside, there are more similarities than differences, so it seems reasonable to consider this a template to extrapolate across the “big pharma” universe. As such, we can understand how it has been viewed positively by most industry pundits.

End game?

Ultimately, the trillion-dollar question remains unanswered in the missing details. Four key uncertainties stand out:

1. MFN scope: If MFN pricing applies only to Medicaid, the industry has effectively secured a major victory at minimal cost. However, with no updates on the GLOBE and GUARD pilots aimed at extending MFN concepts into other programs, it would be premature to assume the process ends here. The risk of a “thin end of the wedge” scenario cannot be dismissed, but some political commentators suggest these programs were only there to serve as part of the “stick” to bring pharma to the negotiating table. Time will tell.
2. TrumpRx: Drugs will be “cheaper” to buy directly – but cheaper than what? Few Americans pay full list prices today, as insurers typically negotiate rebates that halve headline prices while handling all the administration. How will direct purchase interact with insurance coverage? Who bears the administrative cost? If the platform proves cumbersome, public frustration could quickly backfire on its namesake. The initiative appears driven by Trump’s belief – likely reinforced by industry voices – that cutting out “middlemen” will lower costs. That assumption is questionable.
3. Parity pricing for new drugs: Will aligning US launch prices with MFN-basket countries actually lower US prices or simply raise prices abroad? The latter outcome seems more probable, since most foreign markets have limited leverage to extract deeper concessions, as current UK industry negotiations illustrate. The net effect could even turn positive for the industry.
4. Tariff reprieve: While Pfizer’s three-year tariff exemption can seemingly become permanent with sufficient domestic investment, the practical implications are murky. Building FDA-approved manufacturing capacity takes years – so when does the clock start? How long is the reprieve, and what level of CapEx is deemed “enough”? Trump achieves his goals of jobs, tax revenue, and supply security, but it remains uncertain whether pharma companies are truly off the hook on tariffs.

Conclusion – it’s a small win for everyone, but a big win for healthcare investors

Our key takeaway – obvious in hindsight – is that Trump will trade away almost anything to get something “done”. How much does he truly care about drug supply security or lowering consumer prices? His willingness to dilute two distinct policy goals into one agreement suggests either shrewd pragmatism, recognizing a weak negotiating hand, or simple prioritization of headlines over substance.

For the pharmaceutical industry, the message is clear: build more manufacturing capacity in the US and concede modestly on pricing to remove a political irritant. That’s a trade most companies will gladly make. They can even leverage this dynamic internationally – using US compliance as justification to push smaller nations to roll back pricing concessions. As early signs in the UK suggest, those governments may ultimately have little choice but to accept.

Regulatory uncertainty is part of investing in any industry, but the sector has so far escaped the “worst-case” scenarios feared earlier in the year.

Given this outcome – and the growing froth atop the AI and tech complex – it is surely time for investors to re-engage with healthcare. As long as there are people, they will age, fall ill, and need medicines. On that, you can depend.

We always appreciate the opportunity to interact with our investors directly, and you can submit questions regarding the trust at any time via:

shareholder_questions@bellevuehealthcaretrust.com

As ever, we will endeavor to respond in a timely fashion, and we thank you for your continued support during these volatile months.

Paul Major and Brett Darke

Top 10 positions

UnitedHealth Group		5.3%
Thermo Fisher		4.7%
Structure Therapeutics		4.4%
CareDx		4.2%
Iqvia		3.8%
Argenx		3.7%
Danaher		3.6%
AstraZeneca		3.5%
McKesson		3.5%
Abbott Laboratories		3.4%
Total top 10 positions		40.2%
Total positions		45

Sector breakdown

Focused Therapeutics		21.1%
Diagnostics		15.0%
Diversified Therapeutics		12.9%
Med-Tech		11.7%
Services		10.2%
Managed Care		10.0%
Tools		9.0%
Health Tech		4.8%
Distributors		4.8%
Facilities		0.4%
Dental		0.2%

Geographic breakdown

United States		85.2%
Europe		14.8%

Market cap breakdown

Small-Cap		12.4%
Mid-Cap		11.7%
Large-Cap		35.7%
Mega-Cap		40.2%

Benefits

- Healthcare has a strong, fundamental demographic-driven growth outlook.
- The fund has a global and unconstrained investment remit.
- It is a concentrated high conviction portfolio.
- The fund offers a combination of high quality healthcare exposure and a targeted 3.5% dividend yield.
- Bellevue Healthcare Trust has a strong board of directors and relies on the experienced management team of Bellevue Asset Management (UK) Ltd

Inherent risks

- The fund actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Healthcare equities can be subject to sudden substantial price movements owing to market, sector or company factors.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- The fund may take a leverage, which may lead to even higher price movements compared to the underlying market.

You can find a detailed presentation of the risks faced by this fund in the "Risk factors" section of the sales prospectus.

Management Team



Paul Major
Co-Portfolio Manager



Brett Darke
Co-Portfolio Manager

Sustainability Profile – ESG

EU SFDR 2019/2088 product category: Article 8

Exclusions:

Compliance UNGC, HR, ILO	
Norms-based exclusions	
Controversial weapons	

ESG Risk Analysis:

ESG-Integration

Stewardship:

Engagement	
Proxy Voting	

Key Figures:


CO ₂ -intensity (t CO ₂ /mn USD sales):	13.7 (Very low)	Coverage:	92%
MSCI ESG Rating (AAA - CCC):	A	Coverage:	92%

Based on portfolio data as per 30.09.2025; – ESG data base on MSCI ESG Research and are for information purposes only; compliance with global norms according to the principles of UN Global Compact (UNGC), UN Guiding Principles for Business and Human Rights (HR) and standards of International Labor Organisation (ILO); no involvement in controversial weapons; norms-based exclusions based on annual revenue thresholds; ESG Integration: Sustainability risks are considered while performing stock research and portfolio construction; Stewardship: Engagement in an active and constructive dialogue with company representatives on ESG aspects as well as exercising voting rights at general meetings of shareholders. MSCI ESG Rating ranges from "leaders" (AAA-AA), "average" (A, BBB, BB) to "laggards" (B, CCC). The CO₂-intensity expresses MSCI ESG Research's estimate of GHG emissions measured in tons of CO₂ per USD 1 million sales. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in the prospectus. For further information c.f. www.bellevue.ch/sustainability-at-portfolio-level. Please refer to the specific ESG Fund Disclosure and ESG Factsheet for all the characteristics or objectives and employed ESG strategies of the promoted fund.

Source: Bellevue Asset Management, 30.09.2025;
Due to rounding, figures may not add up to 100.0%. Figures are shown as a percentage of gross assets.
For illustrative purposes only. Holdings and allocations are subject to change. Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities. Where the fund is denominated in a currency other than an investor's base currency, changes in the rate of exchange may have an adverse effect on price and income.
Market Cap Breakdown defined as: Mega Cap >\$50bn, Large Cap >\$10bn, Mid-Cap \$2-10bn, Small-Cap \$2bn. Geographical breakdown is on the basis of operational HQ location.

Risk Return Profile acc. to SRI

This product should form part of an investor's overall portfolio. It will be managed with a view to the holding period being not less than three years given the volatility and investment returns that are not correlated to the wider healthcare sector and so may not be suitable for investors unwilling to tolerate higher levels of volatility or uncorrelated returns.



We have rated this product as risk class 6 on a scale of 1 to 7, with 6 being the second highest risk class. The risk of potential losses from future performance is considered high. In the event of very adverse market conditions, it is very likely that the ability to execute your redemption request will be impaired. The calculation of the risk and earnings profile is based on simulated/historical data, which cannot be used as a reliable indication of the future risk profile. The classification of the fund may change in future and does not constitute a guarantee. Even a fund classed in category 1 does not constitute a completely risk-free investment. There can be no guarantee that a return will be achieved or that a substantial loss of capital will not be incurred. The overall risk exposure may have a strong impact on any return achieved by the fund or subfund. For further information please refer to the fund prospectus or PRIIP-KID.

Liquidity risk

The fund may invest some of its assets in financial instruments that may in certain circumstances reach a relatively low level of liquidity, which can have an impact on the fund's liquidity.

Risk arising from the use of derivatives

The fund may conclude derivatives transactions. This increases opportunities, but also involves an increased risk of loss.

Currency risks

The fund may invest in assets denominated in a foreign currency. Changes in the rate of exchange may have an adverse effect on prices and incomes.

Operational risks and custody risks

The fund is subject to risks due to operational or human errors, which can arise at the investment company, the custodian bank, a custodian or other third parties.

Target market

The fund is available for retail and professional investors in the UK who understand and accept its Risk Return Profile.

Objective

The Bellevue Healthcare Trust invests in a concentrated portfolio of listed equities in the global healthcare industry (maximum of 35 holdings). The overall objective for the Bellevue Healthcare Trust is to provide shareholders with capital growth and income over the long term. The Company's specific return objectives are: (i) to beat the total net return of the MSCI World Healthcare Index (in GBP) on a rolling 3 year period and (ii) to seek to generate a total shareholder return of at least 10% p.a., net of fees, over a rolling three-year period. Capital is at risk and there is no guarantee that the positive return will be achieved over the specific, or any, time period.

Important information

This document is only made available to professional clients and eligible counterparties as defined by the Financial Conduct Authority. The rules made under the Financial Services and Markets Act 2000 for the protection of retail clients may not apply and they are advised to speak with their independent financial advisers. The Financial Services Compensation Scheme is unlikely to be available.

Bellevue Healthcare Trust PLC (the "Company") is a UK investment trust premium listed on the London Stock Exchange and is a member of the Association of Investment Companies. As this Company may implement a gearing policy investors should be aware that the share price movement may be more volatile than movements in the price of the underlying investments. **Past performance is not a guide to future performance. The value of an investment and the income from it may fall as well as rise and is not guaranteed. An investor may not get back the original amount invested.** Changes in the rates of exchange between currencies may cause the value of investment to fluctuate. Fluctuation may be particularly marked in the case of a higher volatility fund and the value of an investment may fall suddenly and substantially over time. This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Investment trust share prices may not fully reflect underlying net asset values. There may be a difference between the prices at which you may purchase ("the offer price") or sell ("the bid price") a share on the stock market which is known as the "bid-offer" or "dealing" spread. This is set by the market makers and varies from share to share. This net asset value per share is calculated in accordance with the guidelines of the Association of Investment Companies. The net asset value is stated inclusive of income received. Any opinions on individual stocks are those of the Portfolio Manager and no reliance should be given on such views. This communication has been prepared by Bellevue Asset Management (UK) Ltd., which is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Any research in this document has been procured and may not have been acted upon by Bellevue Asset Management (UK) Ltd. for its own purposes. The results are being made available to you only incidentally. The views expressed herein do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the view of Bellevue Asset Management (UK) Ltd. and no assurances are made as to their accuracy.

© 2025 MSCI ESG Research LLC. Reproduced by permission. Although Bellevue Asset Management information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties make any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

The most important terms are explained in the glossary at www.bellevue.ch/en/glossary.

Copyright © 2025 Bellevue Asset Management AG.